Asian Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

The mRNA Vaccine Heralds a New Era in Vaccinology


Affiliations
1 GES’s Satara College of Pharmacy, Degaon, Satara, 415004, Maharashtra, India
     

   Subscribe/Renew Journal


Vaccination has had a significant impact on infectious diseases control. However, there are still a number of infectious diseases for which an effective vaccine has yet to be developed. There has been a lot of interest in RNA-based technologies for the creation of therapeutic vaccines over the last two decades. The adaptability of mRNA vaccines, as well as their potential to trigger cellular and humoral responses, are among their benefits. Furthermore, because of their intricate interaction with pattern recognition receptors (PRRs), mRNAs have inherent adjuvant qualities. This identification can be advantageous in terms of stimulating antigen-presenting cells (APCs) or harmful in terms of limiting mRNA translation indirectly. We highlight how numerous innate response mechanisms are triggered by mRNA molecules, and how each element, from the 5' cap to the poly-A tail, interferes with innate/adaptive immune responses. mRNA vaccines have the ability to be developed quickly and to be a strong tool in the fight against infectious illnesses. This article provides a thorough overview of mRNA vaccines, including recommendations for future mRNA vaccine development, as well as safety concerns and personalised vaccines. We focused on mRNA delivery and immunological activation, both which have important role for successful mRNA vaccination.

Keywords

Delivery Carriers, Dendritic Cells, Infectious Diseases, Immunity, Mechanism, mRNA, mRNA Vaccine
Subscription Login to verify subscription
User
Notifications
Font Size


  • Halliday, J. "Chapter Twenty-Two - Commercial Aspects of Vaccine Development." Mariusz Skwarczynski and Istvan Toth. Micro- and Nanotechnology in Vaccine Development. William Andrew Publishing, (2017). 411-421. DOI: https://doi.org/10.1016/B978-0-323-39981-4.00022-1

  • Depelsenaire, A.C.I., et al. "Chapter Three - Introduction to Vaccines and Vaccination." Mariusz Skwarczynski, Istvan Toth. Micro and Nanotechnology in Vaccine Development. William Andrew Publishing, (2017). 47-62. DOI: https://doi.org/10.1016/B978-0-323-39981-4.00003-8

  • Pujar, N. S, S. L. Sagar and A. L. Lee. "1- History of Vaccine Process Development." Emily P. Wen, Ronald Ellis and Narahari S. Pujar. Vaccine Development and Manufacturing. First Edition. Hoboken, New Jersey: John Wiley & Sons, Inc., (2015). 1-24.

  • Kellie, S and Z Al-Mansour. "Chapter Four - Overview of the Immune System." Mariusz, Skwarczynski and Toth Istvan. Micro and Nanotechnology in Vaccine Development. William Andrew Publishing, (2017). 63-81. DOI: https://doi.org/10.1016/B978-0-323-39981-4.00004-X

  • Deborah L. Novicki. "Chapter 8 - Introduction to Vaccines and Adjuvants." Lisa M. Plitnick and Danuta J. Herzyk. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Academic Press, (2013). 213-224. DOI: https://doi.org/10.1016/B978-0-12-394810-6.00008-3

  • Plotkin, S. L. and Plotkin, S. A. "1 - A short history of vaccination." Stanley A. Plotkin, Walter A. Orenstein and Paul A. Offit. Vaccines. Sixth Edition. Saunders, (2013). 1-13. DOI: https://doi.org/10.1016/B978-0-323-35761-6.00001-8

  • D’Amico, C, et al. "Development of vaccine formulations: past, present, and future." Drug Delivery and Translational Research 11.2 (2021): 353-372. DOI: https://doi.org/10.1007/s13346-021-00924-7

  • HHS.gov. Vaccine Types. HHS.gov Immunization. [Online] [Cited: 06 09, 2021.] https://www.hhs.gov/immunization/about-us/index.html.

  • Azad, N and Y Rojanasakul. "Vaccine delivery-current trends and future." Current drug delivery 3.2 (2006): 137-146. DOI: https://doi.org/10.2174/156720106776359249

  • Xu, S, et al. "mRNA vaccine era—mechanisms, drug platform and clinical prospection." International Journal of Molecular Sciences 21.18 (2020): 6582. DOI: https://doi.org/10.3390/ijms21186582

  • Lu, Y and M Burnier. "Immunization, Vaccines, and Immunomodulation." Peter Nilsson, Michael Olsen and Stephane Laurent. Early Vascular Aging (EVA). Academic Press, (2015). 347-356.

  • Cao, Y. and Gao, G. F. "mRNA vaccines: A matter of delivery." EClinicalMedicine 32 (2021).

  • Kim, J., et al. "Self-assembled mRNA vaccines." Advanced drug delivery reviews 170 (2021): 83-112.

  • Plotkin, S A. "Vaccines, vaccination, and vaccinology." The Journal of infectious diseases 187.9 (2003): 1349-1359.

  • Warrington, Richard, et al. "An introduction to immunology and immunopathology." Allergy, Asthma & Clinical Immunology 7.1 (2011): 1-8.

  • Tao, X. and Xu, A. "Basic knowledge of immunology." Amphioxus immunity. Academic Press, (2016). 15-42.

  • Verbeke, Rein, et al. "Three decades of messenger RNA vaccine development." Nano Today 28 (2019): 100766.

  • Pardi, N, M J Hogan and D Weissman. "Recent advances in mRNA vaccine technology." Current opinion in immunology 65 (2020): 14-20.

  • Brenner, S., Jacob, F. and Meselson, M. "An unstable intermediate carrying information from genes to ribosomes for protein synthesis." 190.4776 (1961): 576-581.

  • Isaacs, A., R. A. Cox, and Z. Rotem. "Foreign nucleic acids as the stimulus to make interferon." Lancet (1963): 113-16.

  • Furuichi, Yasuhiro, and Kin-Ichiro Miura. "A blocked structure at the 5′ terminus of mRNA from cytoplasmic polyhedrosis virus." Nature 253.5490 (1975): 374-375.

  • Dimitriadis, Giorgos J. "Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes." Nature 274.5674 (1978): 923-924.

  • Krieg, Paul A., and D. A. Melton. "Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs." Nucleic Acids Research 12.18 (1984): 7057-7070.

  • Martinon, Frédéric, et al. "Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA." European journal of immunology 23.7 (1993): 1719-1722.

  • Conry, Robert M., et al. "Characterization of a messenger RNA polynucleotide vaccine vector." Cancer research 55.7 (1995): 1397-1400.

  • Heiser, Axel, et al. "Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors." The Journal of clinical investigation 109.3 (2002): 409-417.

  • Karikó, Katalin, et al. "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA." Immunity 23.2 (2005): 165-175.

  • Karikó, Katalin, et al. "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability." Molecular therapy 16.11 (2008): 1833-1840.

  • Weide, Benjamin, et al. "Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients." Journal of immunotherapy 32.5 (2009): 498-507.

  • Kreiter, Sebastian, et al. "Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity." Cancer research 70.22 (2010): 9031-9040.

  • Petsch, Benjamin, et al. "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection." Nature biotechnology 30.12 (2012): 1210-1216.

  • Geall, Andrew J., et al. "Nonviral delivery of self-amplifying RNA vaccines." Proceedings of the National Academy of Sciences 109.36 (2012): 14604-14609.

  • Sahin, Ugur, et al. "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer." Nature 547.7662 (2017): 222-226.

  • Zhang, Cuiling, et al. "Advances in mRNA vaccines for infectious diseases." Frontiers in Immunology 10 (2019): 594.

  • Blakney, Anna K., Shell Ip, and Andrew J. Geall. "An update on self-amplifying mRNA vaccine development." Vaccines 9.2 (2021): 97.

  • Verbeke, Rein, et al. "The dawn of mRNA vaccines: The COVID-19 case." Journal of Controlled Release 333 (2021): 511-520.

  • Iavarone, Carlo, et al. "Mechanism of action of mRNA-based vaccines." Expert review of vaccines 16.9 (2017): 871-881.

  • Pardi, Norbert, et al. "mRNA vaccines—a new era in vaccinology." Nature reviews Drug discovery 17.4 (2018): 261-279.

  • Zeng, Chunxi, et al. "Formulation and delivery technologies for mRNA vaccines." (2020): 1-40.

  • Midoux, Patrick, and Chantal Pichon. "Lipid-based mRNA vaccine delivery systems." Expert review of vaccines 14.2 (2015): 221-234.

  • Park, Kyung Soo, et al. "Non-viral COVID-19 vaccine delivery systems." Advanced drug delivery reviews (2020).

  • Jabbal-Gill, Inderjit. "Nasal vaccine innovation." Journal of drug targeting 18.10 (2010): 771-786.

  • Belgharbi, Lahouari, Nora Dellepiane, and David J. Wood. "Regulation of vaccines in developing countries." Vaccines. WB Saunders, 2013. 1454-1463.

  • Şenel, Sevda, M. Kürşat Derıcı, and Burcu Devrım. "Regulatory Aspects of Vaccines." FABAD Journal of Pharmaceutical Sciences 45.2 (2020): 153-160.

  • Knezevic, Ivana, et al. "Development of mRNA Vaccines: Scientific and Regulatory Issues." Vaccines 9.2 (2021): 81.

  • Baylor, Norman W., and Valerie B. Marshall. "Regulation and testing of vaccines." Vaccines (2013): 1427.

  • Plitnick, Lisa M. "Global regulatory guidelines for vaccines." Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics. Academic Press, 2013. 225-241.

  • Chen, Gang, et al. "COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says." Frontiers in immunology 12 (2021): 1843.

  • Hou, Changshun, et al. "Up-to-date vaccine delivery systems: robust immunity elicited by multifarious nanomaterials upon administration through diverse routes." Biomaterials science 7.3 (2019): 822-835.

  • Fujita, Y., and H. Taguchi. "Nanoparticle-based peptide vaccines." Micro and Nanotechnology in Vaccine Development. William Andrew Publishing, 2017. 149-170.

  • Tan, Lu, and Xun Sun. "Recent advances in mRNA vaccine delivery." Nano Research 11.10 (2018): 5338-5354.

  • Menon, Ipshita, et al. "Microneedles: A new generation vaccine delivery system." Micromachines 12.4 (2021): 435.

  • Sahin, Ugur, Katalin Karikó, and Özlem Türeci. "mRNA-based therapeutics—developing a new class of drugs." Nature reviews Drug discovery 13.10 (2014): 759-780.

  • Plotkin, Stanley A., and Susan L. Plotkin. "The development of vaccines: how the past led to the future." Nature Reviews Microbiology 9.12 (2011): 889-893.

  • Claire-Anne Siegrist. "2 - Vaccine immunology." Stanley A. Plotkin, Walter A. Orenstein and Paul A. Offit. Vaccines. Sixth Edition. Saunders, (2013). 14-32.

  • Sun, Jing, and Zhibo Li. "Peptoid applications in biomedicine and nanotechnology." Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Woodhead Publishing, 2018. 183-213.

  • Koh, Kai Jun, et al. "Formulation, characterization and evaluation of mRNA-loaded dissolvable polymeric microneedles (RNApatch)." Scientific reports 8.1 (2018): 1-11.

  • Sahu, Itishri, et al. "Recent developments in mRNA-based protein supplementation therapy to target lung diseases." Molecular Therapy 27.4 (2019): 803-823.

  • Noor, Rashed. "Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines." Current clinical microbiology reports (2021): 1-8.

  • Wadhwa, Abishek, et al. "Opportunities and challenges in the delivery of mRNA-based vaccines." Pharmaceutics 12.2 (2020): 102.


Abstract Views: 128

PDF Views: 0




  • The mRNA Vaccine Heralds a New Era in Vaccinology

Abstract Views: 128  |  PDF Views: 0

Authors

Ketaki Shinde
GES’s Satara College of Pharmacy, Degaon, Satara, 415004, Maharashtra, India
Sonam Bendre
GES’s Satara College of Pharmacy, Degaon, Satara, 415004, Maharashtra, India
Niraj Kale
GES’s Satara College of Pharmacy, Degaon, Satara, 415004, Maharashtra, India
Suhit Gilda
GES’s Satara College of Pharmacy, Degaon, Satara, 415004, Maharashtra, India

Abstract


Vaccination has had a significant impact on infectious diseases control. However, there are still a number of infectious diseases for which an effective vaccine has yet to be developed. There has been a lot of interest in RNA-based technologies for the creation of therapeutic vaccines over the last two decades. The adaptability of mRNA vaccines, as well as their potential to trigger cellular and humoral responses, are among their benefits. Furthermore, because of their intricate interaction with pattern recognition receptors (PRRs), mRNAs have inherent adjuvant qualities. This identification can be advantageous in terms of stimulating antigen-presenting cells (APCs) or harmful in terms of limiting mRNA translation indirectly. We highlight how numerous innate response mechanisms are triggered by mRNA molecules, and how each element, from the 5' cap to the poly-A tail, interferes with innate/adaptive immune responses. mRNA vaccines have the ability to be developed quickly and to be a strong tool in the fight against infectious illnesses. This article provides a thorough overview of mRNA vaccines, including recommendations for future mRNA vaccine development, as well as safety concerns and personalised vaccines. We focused on mRNA delivery and immunological activation, both which have important role for successful mRNA vaccination.

Keywords


Delivery Carriers, Dendritic Cells, Infectious Diseases, Immunity, Mechanism, mRNA, mRNA Vaccine

References